Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib

Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib

Authors

  • Daniela Cianniello Oncologia Senologica, Istituto Nazionale Tumori, IRCCS – Fondazione Pascale, Napoli - Italy
  • Roberta Caputo Oncologia Senologica, Istituto Nazionale Tumori, IRCCS – Fondazione Pascale, Napoli

DOI:

https://doi.org/10.19156/abtpn.2018.0044

Keywords:

Metastatic breast cancer, HER2, Lapatinib, Trastuzumab resistance, Pertuzumab resistance

Abstract

Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, progressing after treatment with trastuzumab, pertuzumab and T-DM1, who obtained a regression of hepatic metastases after treatment with lapatinib-capecitabine (Oncology).

Downloads

Download data is not yet available.

Downloads

Published

2018-06-27

How to Cite

Cianniello, D., & Caputo, R. (2018). Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib: Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib. AboutOpen, 4(1), 66–68. https://doi.org/10.19156/abtpn.2018.0044

Metrics